Literature DB >> 29342250

Pneumococcal Community-Acquired Pneumonia Detected by Serotype-Specific Urinary Antigen Detection Assays.

Richard G Wunderink1, Wesley H Self2, Evan J Anderson3,4, Robert Balk5, Sherene Fakhran6, Daniel Mark Courtney1, Chao Qi1, Derek J Williams2, Yuwei Zhu2, Cynthia G Whitney7, Matthew R Moore7, Anna Bramley7, Seema Jain7, Kathryn M Edwards2, Carlos G Grijalva2,8.   

Abstract

Background: Streptococcus pneumoniae is considered the leading bacterial cause of pneumonia in adults. Yet, it was not commonly detected by traditional culture-based and conventional urinary testing in a recent multicenter etiology study of adults hospitalized with community-acquired pneumonia (CAP). We used novel serotype-specific urinary antigen detection (SSUAD) assays to determine whether pneumococcal cases were missed by traditional testing.
Methods: We studied adult patients hospitalized with CAP at 5 hospitals in Chicago and Nashville (2010-2012) and enrolled in the Etiology of Pneumonia in the Community (EPIC) study. Traditional diagnostic testing included blood and sputum cultures and conventional urine antigen detection (ie, BinaxNOW). We applied SSUAD assays that target serotypes included in the 13-valent pneumococcal conjugate vaccine (PCV13) to stored residual urine specimens.
Results: Among 1736 patients with SSUAD and ≥1 traditional pneumococcal test performed, we identified 169 (9.7%) cases of pneumococcal CAP. Traditional tests identified 93 (5.4%) and SSUAD identified 76 (4.4%) additional cases. Among 14 PCV13-serotype cases identified by culture, SSUAD correctly identified the same serotype in all of them. Cases identified by SSUAD vs traditional tests were similar in most demographic and clinical characteristics, although disease severity and procalcitonin concentration were highest among those with positive blood cultures. The proportion of pneumonia cases caused by serotypes exclusively covered by PCV13 was not significantly different between the first and second July-June study periods (6.4% vs 4.0%). Conclusions: Although restricted to the detection of only 13 serotypes, SSUAD testing substantially increased the detection of pneumococcal pneumonia among adults hospitalized with CAP.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29342250      PMCID: PMC5930250          DOI: 10.1093/cid/cix1066

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  39 in total

1.  PNEUMOCOCCAL BACTEREMIA WITH ESPECIAL REFERENCE TO BACTEREMIC PNEUMOCOCCAL PNEUMONIA.

Authors:  R AUSTRIAN; J GOLD
Journal:  Ann Intern Med       Date:  1964-05       Impact factor: 25.391

2.  Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial.

Authors:  Mirjam Christ-Crain; Daiana Jaccard-Stolz; Roland Bingisser; Mikael M Gencay; Peter R Huber; Michael Tamm; Beat Müller
Journal:  Lancet       Date:  2004-02-21       Impact factor: 79.321

3.  Community-Acquired Pneumonia Requiring Hospitalization.

Authors:  Daniel M Musher; Michael S Abers
Journal:  N Engl J Med       Date:  2015-12-10       Impact factor: 91.245

Review 4.  Diagnostic tests for agents of community-acquired pneumonia.

Authors:  John G Bartlett
Journal:  Clin Infect Dis       Date:  2011-05       Impact factor: 9.079

5.  Influence of Antibiotics on the Detection of Bacteria by Culture-Based and Culture-Independent Diagnostic Tests in Patients Hospitalized With Community-Acquired Pneumonia.

Authors:  Aaron M Harris; Anna M Bramley; Seema Jain; Sandra R Arnold; Krow Ampofo; Wesley H Self; Derek J Williams; Evan J Anderson; Carlos G Grijalva; Jonathan A McCullers; Andrew T Pavia; Richard G Wunderink; Kathryn M Edwards; Jonas M Winchell; Lauri A Hicks
Journal:  Open Forum Infect Dis       Date:  2017-02-10       Impact factor: 3.835

6.  Exposure to children as a risk factor for bacteremic pneumococcal disease: changes in the post-conjugate vaccine era.

Authors:  Joshua P Metlay; Ebbing Lautenbach; Yimei Li; Justine Shults; Paul H Edelstein
Journal:  Arch Intern Med       Date:  2010-04-26

7.  Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance.

Authors:  Matthew R Moore; Ruth Link-Gelles; William Schaffner; Ruth Lynfield; Catherine Lexau; Nancy M Bennett; Susan Petit; Shelley M Zansky; Lee H Harrison; Arthur Reingold; Lisa Miller; Karen Scherzinger; Ann Thomas; Monica M Farley; Elizabeth R Zell; Thomas H Taylor; Tracy Pondo; Loren Rodgers; Lesley McGee; Bernard Beall; James H Jorgensen; Cynthia G Whitney
Journal:  Lancet Infect Dis       Date:  2015-02-03       Impact factor: 25.071

8.  Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the USA: a time-series analysis.

Authors:  Carlos G Grijalva; J Pekka Nuorti; Patrick G Arbogast; Stacey W Martin; Kathryn M Edwards; Marie R Griffin
Journal:  Lancet       Date:  2007-04-07       Impact factor: 79.321

9.  Procalcitonin guided antibiotic therapy and hospitalization in patients with lower respiratory tract infections: a prospective, multicenter, randomized controlled trial.

Authors:  Philipp Schuetz; Mirjam Christ-Crain; Marcel Wolbers; Ursula Schild; Robert Thomann; Claudine Falconnier; Isabelle Widmer; Stefanie Neidert; Claudine A Blum; Ronald Schönenberger; Christoph Henzen; Thomas Bregenzer; Claus Hoess; Martin Krause; Heiner C Bucher; Werner Zimmerli; Beat Müller
Journal:  BMC Health Serv Res       Date:  2007-07-05       Impact factor: 2.655

10.  Comprehensive Molecular Testing for Respiratory Pathogens in Community-Acquired Pneumonia.

Authors:  Naomi J Gadsby; Clark D Russell; Martin P McHugh; Harriet Mark; Andrew Conway Morris; Ian F Laurenson; Adam T Hill; Kate E Templeton
Journal:  Clin Infect Dis       Date:  2016-01-07       Impact factor: 9.079

View more
  15 in total

Review 1.  Impact of pneumococcal conjugate vaccines on hospitalizations for pneumonia in the United States.

Authors:  Andrew D Wiese; Marie R Griffin; Carlos G Grijalva
Journal:  Expert Rev Vaccines       Date:  2019-03-20       Impact factor: 5.217

2.  What Fraction of Adult Community-Acquired Pneumonia Is Caused by the Pneumococcus? New Insights from Spain.

Authors:  Carlos G Grijalva
Journal:  Clin Infect Dis       Date:  2021-09-15       Impact factor: 9.079

3.  Effectiveness of 13-Valent Pneumococcal Conjugate Vaccine Against Hospitalization for Community-Acquired Pneumonia in Older US Adults: A Test-Negative Design.

Authors:  John M McLaughlin; Qin Jiang; Raul E Isturiz; Heather L Sings; David L Swerdlow; Bradford D Gessner; Ruth M Carrico; Paula Peyrani; Timothy L Wiemken; William A Mattingly; Julio A Ramirez; Luis Jodar
Journal:  Clin Infect Dis       Date:  2018-10-30       Impact factor: 9.079

4.  Non-lytic antibiotic treatment in community-acquired pneumococcal pneumonia does not attenuate inflammation: the PRISTINE trial.

Authors:  Geert H Groeneveld; Tanny J van der Reyden; Simone A Joosten; Hester J Bootsma; Christa M Cobbaert; Jutte J C de Vries; Ed J Kuijper; Jaap T van Dissel
Journal:  J Antimicrob Chemother       Date:  2019-08-01       Impact factor: 5.790

5.  BioFire® FilmArray® Pneumonia Panel for Severe Lower Respiratory Tract Infections: Subgroup Analysis of a Randomized Clinical Trial.

Authors:  Evdoxia Kyriazopoulou; Athanasios Karageorgos; Lydia Liaskou-Antoniou; Panagiotis Koufargyris; Asimina Safarika; Georgia Damoraki; Vasileios Lekakis; Maria Saridaki; George Adamis; Evangelos J Giamarellos-Bourboulis
Journal:  Infect Dis Ther       Date:  2021-06-13

6.  Epidemiology of hospitalised paediatric community-acquired pneumonia and bacterial pneumonia following the introduction of 13-valent pneumococcal conjugate vaccine in the national immunisation programme in Japan.

Authors:  N Takeuchi; S Naito; M Ohkusu; K Abe; K Shizuno; Y Takahashi; Y Omata; T Nakazawa; K Takeshita; H Hishiki; T Hoshino; Y Sato; N Ishiwada
Journal:  Epidemiol Infect       Date:  2020-04-17       Impact factor: 2.451

7.  Distribution of 13-Valent pneumococcal conjugate vaccine serotype streptococcus pneumoniae in adults 50 Years and Older presenting with community-acquired pneumonia in Israel.

Authors:  Gili Regev-Yochay; Michal Chowers; Bibiana Chazan; Elisa Gonzalez; Sharon Gray; Zhou Zhang; Michael Pride
Journal:  Hum Vaccin Immunother       Date:  2018-09-06       Impact factor: 3.452

8.  Decision-making for PCV in adults.

Authors:  John M McLaughlin; David L Swerdlow; Raul E Isturiz; Luis Jodar
Journal:  Hum Vaccin Immunother       Date:  2018-12-10       Impact factor: 3.452

Review 9.  Recent advances in the epidemiology and prevention of Streptococcus pneumoniae infections.

Authors:  Charles Feldman; Ronald Anderson
Journal:  F1000Res       Date:  2020-05-07

10.  Age-stratified burden of pneumococcal community acquired pneumonia in hospitalised Canadian adults from 2010 to 2015.

Authors:  Jason LeBlanc; May ElSherif; Lingyun Ye; Donna MacKinnon-Cameron; Ardith Ambrose; Todd F Hatchette; Amanda Ls Lang; Hayley D Gillis; Irene Martin; Walter H Demczuk; Craig LaFerriere; Melissa K Andrew; Guy Boivin; William Bowie; Karen Green; Jennie Johnstone; Mark Loeb; Anne McCarthy; Allison McGeer; Makeda Semret; Sylvie Trottier; Louis Valiquette; Duncan Webster; Shelly A McNeil
Journal:  BMJ Open Respir Res       Date:  2020-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.